Skip to main content

Advertisement

SpringerLink
Log in

Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia

  • Original Article – Clinical Oncology
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Purpose

To explore therapy-goals and patients’ expectations regarding discontinuing tyrosine kinase inhibitors (TKIs) therapy in Chinese with chronic myeloid leukemia (CML). To identify variables associated with these expectations and preferences.

Methods

Noninterventional, cross-sectional study using questionnaires distributed to persons with CML and answered anonymously.

Results

With CML in chronic phase, 888 respondents were evaluable. In total, 513 respondents (58 %) were male. Median age was 41 years (range 18–88 years). Median TKI therapy duration was 3 years (range <1–13 years). In total, 735 respondents (83 %) paid part or all of the cost of TKI. As their treatment goal, 430 of 888 respondents (48 %) reported treatment-free remission (TFR). In the future, 734 respondents (83 %) expected to discontinue TKI. Multivariate analyses confirmed younger age [HR = 1.3; (1.1, 1.4); P < 0.001] and higher out-of-pocket expense [HR = 1.2; (1.1, 1.4); P < 0.001] were associated with TFR as a therapy-goal. Both variables were also associated with patients’ hope to stop TKI therapy in the future: HR = 1.4; (0.8, 1.7; P < 0.001) and HR = 1.5; (1.3, 1.8; P < 0.001). Achieving a complete molecular response [HR = 1.8 (1.1, 2.9); P = 0.017] and decreased quality of life resulting from adverse effects [HR = 1.2; (1.0, 1.5); P = 0.021] were factors associated with the expectation of discontinuing TKI therapy.

Conclusions

Younger age and higher out-of-pocket cost are associated with patients’ preference for stopping TKI therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  • Apperley JF (2015) Chronic myeloid leukemia. Lancet (London, England) 385:1447–1459

    Article  Google Scholar 

  • Arora NK, McHorney CA (2000) Patient preferences for medical decision making: who really wants to participate? Med Care 38:335–341

    Article  CAS  PubMed  Google Scholar 

  • Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Blood 122:872–884

    Article  CAS  PubMed  Google Scholar 

  • Breccia M, Alimena G (2014) Discontinuation of tyrosine kinase inhibitors and new approaches to target leukemic stem cells: treatment-free remission as a new goal in chronic myeloid leukemia. Cancer Lett 347:22–28

    Article  CAS  PubMed  Google Scholar 

  • Brom L, Pasman HRW, Widdershoven GAM et al (2014) Patients’ preferences for participation in treatment decision-making at the end of life: qualitative interviews with advanced cancer patients. PLoS One 9(6):e100435

    Article  PubMed  PubMed Central  Google Scholar 

  • Cortes JE, Baccarani M, Guilhot F et al (2010) Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. J Clin Oncol 28:424–430

    Article  CAS  PubMed  Google Scholar 

  • Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL (2014) Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 32:306–311

    Article  PubMed  Google Scholar 

  • Efficace F, Baccarani M, Breccia M et al (2011) Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood 118:4554–4560

    Article  CAS  PubMed  Google Scholar 

  • Gambacorti-Passerini C, Antolini L, Mahon F-X et al (2011) Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 103:553–561

    Article  CAS  PubMed  Google Scholar 

  • Ganesan P, Sagar TG, Dubashi B et al (2011) Non-adherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia. Am J Hematol 86:471–474

    Article  PubMed  Google Scholar 

  • Ibrahim AR, Eliasson L, Apperley JF et al (2011) Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 117:3733–3736

    Article  CAS  PubMed  Google Scholar 

  • Jiang Q, Gale RP (2016) Molecular monitoring of tyrosine kinase inhibitor therapy of chronic myeloid leukemia in China. J Cancer Res Clin Oncol (accepted)

  • Kantarjian HM, Hochhaus A, Saglio G et al (2011) Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukemia: 24-month minimum follow-up of the phase 3 randomized ENESTnd trial. Lancet Oncol 12:841–851

    Article  CAS  PubMed  Google Scholar 

  • Kapoor J, Agrawal N, Ahmed R et al (2015) Factors influencing adherence to imatinib in Indian chronic myeloid leukemia patients: a cross-sectional study. Mediterr J Hematol Infect Dis 7:e2015013

    Article  PubMed  PubMed Central  Google Scholar 

  • Kekäle M, Talvensaari K, Koskenvesa P, Porkka K, Airaksinen M (2014) Chronic myeloid leukemia patients’ adherence to per-oral tyrosine kinase inhibitors compared with adherence as estimated by their physicians. Patient Prefer Adherence 8:1619–1627

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim D-W, Banavali SD, Bunworasate U et al (2010) Chronic myeloid leukemia in the Asia-Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res 34:1459–1471

    Article  PubMed  Google Scholar 

  • Kodama Y, Morozumi R, Matsumura T et al (2012) Increased financial burden among patients with chronic myelogenous leukemia receiving imatinib in Japan: a retrospective survey. BMC Cancer 12:152

    Article  PubMed  PubMed Central  Google Scholar 

  • Mahon FX, Réa D, Guilhot J et al (2010) Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029–1035

    Article  CAS  PubMed  Google Scholar 

  • Marin D, Bazeos A, Mahon FX et al (2010) Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 28:2381–2388

    Article  CAS  PubMed  Google Scholar 

  • Mühlbacher AC, Bethge S (2015) Patients’ preferences: a discrete-choice experiment for treatment of non-small-cell lung cancer. Eur J Health Econ 16:657–670

    Article  PubMed  Google Scholar 

  • National Comprehensive Cancer Network (2016) NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia version 1. Fort Washington PA. National Comprehensive Care Network. 2015. http://www.nccn.org/professionals/physician_gls/pdf/cml.pdf. Accessed 26 March 2016

  • Noens L, Van Lierde MA, De Bock R et al (2009) Prevalence, determinants, and outcomes of non-adherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood 113:5401–5411

    Article  CAS  PubMed  Google Scholar 

  • Rousselot P, Huguet F, Rea D et al (2007) Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood 109:58–60

    Article  CAS  PubMed  Google Scholar 

  • Sanford D, Kyle R, Lazo-Langner A et al (2014) Patient preferences for stopping tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Oncol 21:e241–e249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang A-H, Wang Y-Y, Yao Y et al (2010) Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006. J Exp Clin Cancer Res 29:20

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author contributions

JQ designed the study, collected, analyzed and interpreted the data, and drafted the article. LZC designed the study. ZSX collected the data. RPG interpreted the data and drafted the article. All authors read and approved the final typescript.

Funding

This study was funded by National Natural Science Foundation of China (No. 81370637). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme.

Author information

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, 11 Xizhimen South Street, Beijing, 100044, China

    Qian Jiang

  2. Collaborative Innovation Center of Hematology, Soochow University, Suzhou, People’s Republic of China

    Qian Jiang

  3. New Sunshine Charity Foundation, Beijing, China

    Zheng-Chen Liu & Song-Xin Zhang

  4. Division of Experimental Medicine, Department of Medicine, Haematology Research Centre, Imperial College London, London, UK

    Robert Peter Gale

Authors
  1. Qian Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zheng-Chen Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Song-Xin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert Peter Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Qian Jiang.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

All procedures involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Because the survey used anonymous questionnaires, the Ethics Committee of Peoples Hospital determined informed consent of participants was not required.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 25 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, Q., Liu, ZC., Zhang, SX. et al. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia. J Cancer Res Clin Oncol 142, 1539–1547 (2016). https://doi.org/10.1007/s00432-016-2159-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-016-2159-7

Keywords

Search

Navigation